Gleevec Wins Regular Approval as GIST Adjuvant
WASHINGTON (MedPage Today) — The provisional approval of imatinib (Gleevec) as adjuvant therapy for a certain form of gastrointestinal stromal tumor has been made permanent, the FDA announced.
WASHINGTON (MedPage Today) — The provisional approval of imatinib (Gleevec) as adjuvant therapy for a certain form of gastrointestinal stromal tumor has been made permanent, the FDA announced.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.